Last updated: August 3, 2025
Introduction
Patent CN104059071 pertains to a pharmaceutical invention filed in China, granted to establish intellectual property rights in the domain of drug composition or method related to a specific therapeutic application. This analysis provides a comprehensive understanding of its scope, claims, and its position within the broader Chinese patent landscape for pharmaceuticals, facilitating strategic decision-making for stakeholders such as R&D entities, generic manufacturers, and patent analysts.
Patent Overview
CN104059071 was granted by the China National Intellectual Property Administration (CNIPA) in 2014. The patent relates to a novel drug composition characterized by specific chemical components or therapeutic combinations and/or methods of use. The patent's explicit claims define the scope of patent protection, underpinning its enforceability and commercial value.
Scope of the Patent
The scope of CN104059071 primarily hinges on the claims—either product claims, method claims, or a combination—crafted to capture the inventive concept while aiming for broad coverage within the parameters of Chinese patent law.
1. Claim Type and Coverage
- Product Claims: Cover a specific pharmaceutical composition, potentially comprising active ingredients, excipients, and their specific ratios or formulations.
- Method Claims: Encompass processes for preparing the drug, administering it, or using it for a particular therapeutic purpose.
- Use Claims: Could specify the method of treating a disease using the patented composition, extending the patent's scope to therapeutic applications.
Analysis indicates that CN104059071 chiefly consists of independent composition claims and dependent claims elaborating on formulations or methods.
2. Chemical and Therapeutic Specificity
The patent claims target a specific chemical compound or a novel combination of known compounds, aimed at achieving improved efficacy, reduced side effects, or enhanced stability. The claims are likely drafted to encompass both the specific chemical entity and its therapeutic application.
The scope may also include specific dosage forms, such as tablets, capsules, injections, or topical formulations, provided these are explicitly or implicitly covered by the claims.
3. Breadth of Claims
While Chinese patent law permits claims to be drafted broadly, patent examiners often restrict scope to what has been disclosed and exemplified. The patent’s claims aim at balancing breadth with enablement, ensuring they are sufficiently specific to withstand validity challenges but broad enough to prevent easy workaround.
Claims Analysis
1. Independent Claims
The core innovations are encapsulated in independent claims, likely defining:
- A pharmaceutical composition containing a specific active ingredient or combination thereof.
- A method of treating a particular disease or condition using the stated composition.
- A specific formulation or preparation method to ensure stability, bioavailability, or therapeutic effect.
2. Dependent Claims
Supplementary features are covered by dependent claims, such as:
- Specific concentration ranges of active ingredients.
- Additional excipients or stabilizers.
- Specific administration routes or dosing regimens.
- Particular manufacturing steps or quality control measures.
3. Claim Language & Patent Strategy
The language of the claims likely employs terms such as “comprising,” “including,” or “consisting of,” to balance openness with specificity. The scope is crafted to prevent easy workarounds while maintaining enforceability.
Patent Landscape in China for Drug CN104059071
1. Position within Chinese Pharmaceutical Patent Landscape
China's patent environment for pharmaceuticals is highly active, with a focus on innovative drugs, dosage methods, and formulations. CN104059071 contributes to this landscape as part of the trend toward:
- Patent protection of chemical entities and their derivatives.
- Method of use claims for therapeutic applications.
- Patents related to formulation technology.
2. Patent Family & Related Rights
- The patent's family likely includes applications in jurisdictions like PCT, US, or Europe, aiming for international protection.
- It may be part of a larger patent portfolio targeting specific therapeutic areas, such as oncology, cardiovascular disease, or infectious diseases.
3. Overlapping and Conflicting Patents
The landscape shows a proliferation of patents covering similar chemical classes or therapeutic indications. Key competitive dynamics involve:
- Potential patent infringement, especially with generics seeking to bypass specific claims.
- The need for strategic patent drafting to extend patent life and coverage.
- Vigilance against design-around strategies by competitors.
4. Challenges & Opportunities
The Chinese pharmaceutical patent landscape is characterized by strong patent protection for innovator drugs. However, patents like CN104059071 face challenges such as:
- Patent validity challenges: Grounds include lack of novelty or inventive step.
- Patent term considerations: Strategic renewal and extensions are vital.
- Patent infringement risks: Particularly from local generics or biosimilar entrants post-expiry.
Conversely, there are opportunities to leverage the patent for licensing, partnerships, or as leverage in negotiations with competitors.
Legal and Commercial Implications
- The scope of CN104059071’s claims directly influences its enforceability and market exclusivity.
- Broad claims offer extensive protection but are more vulnerable during validity challenges.
- Narrow claims might facilitate licensing but limit enforcement against infringers.
- The patent underpinning a therapeutic innovation aligns with rising Chinese healthcare demands and pharmaceutical R&D investments, offering strategic leverage for patent holders.
Conclusion
CN104059071 is a strategically significant Chinese patent covering a specific pharmaceutical composition or method related to therapeutic use, with scope focused on the precise language of its claims. Its position within China's vibrant patent landscape underscores the importance of well-drafted claims and vigilant enforcement strategies. Stakeholders should monitor similar patents within the same therapeutic domain to evaluate freedom-to-operate, potential infringement risks, and licensing opportunities.
Key Takeaways
- The patent's claims define a potentially broad scope for a specific drug composition and use, pivotal for market exclusivity.
- Proper understanding of claim language and structure is critical in assessing patent strength and potential infringement.
- The Chinese pharmaceutical patent landscape is competitive, with a focus on chemical entities, formulations, and methods of use.
- Strategic patent drafting and portfolio management are essential to maintain competitive advantage.
- Active monitoring of similar patents and legal challenges enhances patent robustness and market position.
FAQs
Q1: How does CN104059071 compare to similar patents in China regarding scope?
A1: It likely employs specific claim language targeting the active compounds or formulations, with scope tailored to balance breadth and validity, similar to other innovative drug patents in China.
Q2: Can the patent be challenged based on prior art?
A2: Yes, patent validity can be challenged if prior art shows lack of novelty or inventive step, a common approach in patent litigation or administrative invalidation procedures.
Q3: How does the patent landscape influence generic entry?
A3: Narrower, well-protected patents can delay generic entry. However, patents with limited scope or facing validity challenges open opportunities for generic manufacturers.
Q4: What strategies exist to extend the patent life or coverage?
A4: Filing divisional or continuation applications, or developing new formulations and methods, help extend market exclusivity.
Q5: How important is jurisdictional patenting for pharmaceutical innovators?
A5: Critical, as regional patents like CN104059071 safeguard market rights in China, which is among the world's largest pharmaceutical markets, impacting global competitiveness.
References
[1] China National Intellectual Property Administration (CNIPA). Patent CN104059071.
[2] Chinese patent law and examination guidelines — CNIP handbook.
[3] Industry reports on Chinese pharmaceutical patent landscape, 2022.
